Data Management Core The Data Management Core is responsible for both the data management and computing needs of the SWOG SDMC. The Data Management Core provides management processes and procedures for delivering high quality and timely data on clinical trials. Specific goals include the following: (a) develop and optimize systems for the complete and timely collection, review, secure storage and retrieval of the highest quality data, complementing Medidata Rave and other standardized NCTN tools; (b) ensure timely and accurate adverse event monitoring and reporting; and (c) enhance existing and develop new software to best track patient specimens and translational medicine data and expand the use of the SWOG biorepository to the research community. The SWOG SDMC, primarily through the Data Management Core, facilitates these activities to ensure high quality and timely data using improved data forms, standardized data definitions, and reporting systems to maximize accuracy, and by providing education to investigators and site oncology research professionals on best practices for data management and electronic data capture principles. The SWOG Data Management Core has a significant history of developing high quality and innovative cross- trial software programs to enhance existing NCI tools to best manage data activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180819-06
Application #
9628433
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Halpern, Anna B; Othus, Megan; Huebner, Emily M et al. (2018) Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia :
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
Unger, Joseph M; Vaidya, Riha; Gore, John L (2018) Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urol Oncol :
Cheng, Ting-Yuan David; Darke, Amy K; Redman, Mary W et al. (2018) Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst 110:734-742
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Walter, Roland B; Michaelis, Laura C; Othus, Megan et al. (2018) Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol 93:E49-E52
Othus, Megan; Estey, Elihu H; Garcia-Manero, Guillermo et al. (2018) Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia :
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504

Showing the most recent 10 out of 156 publications